vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and TIDEWATER INC (TDW). Click either name above to swap in a different company.
TIDEWATER INC is the larger business by last-quarter revenue ($336.8M vs $268.1M, roughly 1.3× ACADIA PHARMACEUTICALS INC). TIDEWATER INC runs the higher net margin — 65.3% vs 1.4%, a 63.9% gap on every dollar of revenue. On growth, ACADIA PHARMACEUTICALS INC posted the faster year-over-year revenue change (9.7% vs -2.4%). Over the past eight quarters, ACADIA PHARMACEUTICALS INC's revenue compounded faster (5.3% CAGR vs 2.4%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
Tidewater, Inc. is a publicly traded international petroleum service company headquartered in Houston, Texas, U.S. It operates a fleet of ships, primarily providing vessels and marine services to the offshore petroleum and offshore wind industries.
ACAD vs TDW — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $268.1M | $336.8M |
| Net Profit | $3.6M | $219.9M |
| Gross Margin | — | — |
| Operating Margin | -1.7% | 19.0% |
| Net Margin | 1.4% | 65.3% |
| Revenue YoY | 9.7% | -2.4% |
| Net Profit YoY | — | 495.8% |
| EPS (diluted) | $0.02 | $4.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $268.1M | — | ||
| Q4 25 | $284.0M | $336.8M | ||
| Q3 25 | $278.6M | $341.1M | ||
| Q2 25 | $264.6M | $341.4M | ||
| Q1 25 | $244.3M | $333.4M | ||
| Q4 24 | $259.6M | $345.1M | ||
| Q3 24 | $250.4M | $340.4M | ||
| Q2 24 | $242.0M | $339.2M |
| Q1 26 | $3.6M | — | ||
| Q4 25 | $273.6M | $219.9M | ||
| Q3 25 | $71.8M | $-806.0K | ||
| Q2 25 | $26.7M | $72.9M | ||
| Q1 25 | $19.0M | $42.7M | ||
| Q4 24 | $143.7M | $36.9M | ||
| Q3 24 | $32.8M | $46.4M | ||
| Q2 24 | $33.4M | $50.4M |
| Q1 26 | — | — | ||
| Q4 25 | 90.8% | — | ||
| Q3 25 | 92.2% | — | ||
| Q2 25 | 92.2% | — | ||
| Q1 25 | 91.7% | — | ||
| Q4 24 | 91.6% | — | ||
| Q3 24 | 92.5% | — | ||
| Q2 24 | 92.5% | — |
| Q1 26 | -1.7% | — | ||
| Q4 25 | 6.1% | 19.0% | ||
| Q3 25 | 12.8% | 18.4% | ||
| Q2 25 | 12.2% | 23.7% | ||
| Q1 25 | 7.9% | 22.5% | ||
| Q4 24 | 59.1% | 23.6% | ||
| Q3 24 | 12.6% | 20.6% | ||
| Q2 24 | 12.6% | 23.0% |
| Q1 26 | 1.4% | — | ||
| Q4 25 | 96.3% | 65.3% | ||
| Q3 25 | 25.8% | -0.2% | ||
| Q2 25 | 10.1% | 21.4% | ||
| Q1 25 | 7.8% | 12.8% | ||
| Q4 24 | 55.4% | 10.7% | ||
| Q3 24 | 13.1% | 13.6% | ||
| Q2 24 | 13.8% | 14.8% |
| Q1 26 | $0.02 | — | ||
| Q4 25 | $1.61 | $4.37 | ||
| Q3 25 | $0.42 | $-0.02 | ||
| Q2 25 | $0.16 | $1.46 | ||
| Q1 25 | $0.11 | $0.83 | ||
| Q4 24 | $0.86 | $0.70 | ||
| Q3 24 | $0.20 | $0.87 | ||
| Q2 24 | $0.20 | $0.94 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $578.8M |
| Total DebtLower is stronger | — | $670.1M |
| Stockholders' EquityBook value | — | $1.4B |
| Total Assets | $1.6B | $2.4B |
| Debt / EquityLower = less leverage | — | 0.49× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $177.7M | $578.8M | ||
| Q3 25 | $258.0M | $428.2M | ||
| Q2 25 | $253.6M | $369.4M | ||
| Q1 25 | $217.7M | $341.8M | ||
| Q4 24 | $319.6M | $324.9M | ||
| Q3 24 | $155.1M | $280.8M | ||
| Q2 24 | $177.1M | $315.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | $670.1M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $647.9M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | $1.2B | $1.4B | ||
| Q3 25 | $917.3M | $1.1B | ||
| Q2 25 | $822.4M | $1.1B | ||
| Q1 25 | $765.2M | $1.1B | ||
| Q4 24 | $732.8M | $1.1B | ||
| Q3 24 | $577.2M | $1.1B | ||
| Q2 24 | $516.7M | $1.1B |
| Q1 26 | $1.6B | — | ||
| Q4 25 | $1.6B | $2.4B | ||
| Q3 25 | $1.3B | $2.1B | ||
| Q2 25 | $1.2B | $2.1B | ||
| Q1 25 | $1.1B | $2.1B | ||
| Q4 24 | $1.2B | $2.1B | ||
| Q3 24 | $976.9M | $2.0B | ||
| Q2 24 | $914.1M | $2.1B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.49× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.58× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $153.0M |
| Free Cash FlowOCF − Capex | — | $147.8M |
| FCF MarginFCF / Revenue | — | 43.9% |
| Capex IntensityCapex / Revenue | — | 1.5% |
| Cash ConversionOCF / Net Profit | — | 0.70× |
| TTM Free Cash FlowTrailing 4 quarters | — | $353.3M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-48.7M | $153.0M | ||
| Q3 25 | $74.3M | $54.7M | ||
| Q2 25 | $64.0M | $85.4M | ||
| Q1 25 | $20.3M | $86.0M | ||
| Q4 24 | $40.4M | $100.0M | ||
| Q3 24 | $63.2M | $49.0M | ||
| Q2 24 | $25.0M | $78.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | $147.8M | ||
| Q3 25 | $73.9M | $49.6M | ||
| Q2 25 | — | $80.2M | ||
| Q1 25 | — | $75.7M | ||
| Q4 24 | — | $95.5M | ||
| Q3 24 | $63.2M | $43.3M | ||
| Q2 24 | — | $72.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | 43.9% | ||
| Q3 25 | 26.5% | 14.5% | ||
| Q2 25 | — | 23.5% | ||
| Q1 25 | — | 22.7% | ||
| Q4 24 | — | 27.7% | ||
| Q3 24 | 25.2% | 12.7% | ||
| Q2 24 | — | 21.3% |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.5% | ||
| Q3 25 | 0.1% | 1.5% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 3.1% | ||
| Q4 24 | — | 1.3% | ||
| Q3 24 | 0.0% | 1.7% | ||
| Q2 24 | — | 1.9% |
| Q1 26 | — | — | ||
| Q4 25 | -0.18× | 0.70× | ||
| Q3 25 | 1.03× | — | ||
| Q2 25 | 2.40× | 1.17× | ||
| Q1 25 | 1.07× | 2.02× | ||
| Q4 24 | 0.28× | 2.71× | ||
| Q3 24 | 1.93× | 1.06× | ||
| Q2 24 | 0.75× | 1.56× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
